In vitro antifungal susceptibility of clinical isolates of Candida spp. obtained from patients with different predisposing factors to candidosis

Microbiological Research

Volumn 163, Issue 5, 2008, Pages 579-585

  Pinto, Patrícia M ^a   Weikert Oliveira, Rita de Cássia Botelho ^a   Lyon, Juliana Pereira ^a   Cury, Verônica F ^a   Arantes, Rodrigo R ^a   Koga Ito, Cristiane Y ^a   Resende, Maria A ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Amphotericin B; Candida; Fluconazole; Flucytosine; Itraconazole

Indexed keywords

CHEMOTHERAPY; DRUG DELIVERY; DRUG DOSAGE; STANDARDS;

ALBICANS; AMPHOTERICIN; AMPHOTERICIN B; ANTI-FUNGAL; ANTIFUNGAL AGENTS; CANDIDA; CANDIDA SPECIES; CLINICAL ISOLATES; FLUCONAZOLE; FLUCYTOSINE; IN-VITRO; ITRACONAZOLE; PREDISPOSING FACTORS;

FUNGICIDES;

ANTIMICROBIAL ACTIVITY; BIOASSAY; DRUG; FUNGAL DISEASE;

CANDIDA; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS;

EID: 48749083631     PISSN: 09445013     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.micres.2006.08.007     Document Type: Article

References (27)

1. Odds F.C. Factors that predispose the host to candidosis. In: Odds F.C. (Ed). Candida and Candidosis (1988), Bailiière Tindall, London 71-74
2. Budtz-Jorgensen E. Etiology, pathogenesis, therapy and prophylaxis of yeast infection. Acta Odontol. Scand. 48 (1990) 61-69
3. Jorge A.O.C., Koga-Ito C.Y., and Gonçalves C.R. Presença de Leveduras do Gênero Candida na Saliva de Pacientes com Diferentes Fatores Predisponentes e de Indivíduos Controle. Ver. Odontol. Univ. São Paulo 11 (1997) 279-285
4. Vidotto, V., 1997. Metabolismo dei lieviti. In: Vidotto, V. Micologia Medica. Editora Masson, Milão. pp. 49-56.
5. Odds F.C. Resistance of yeasts to azole - derivative antifungals. J. Antimicrob. Chemother. 39 (1993) 1696-1699
6. Rex J.H. Detection of amphotericin B-resistent Candida isolates in a broth-based system. Antimicrob. Agents Chemother. 39 (1995) 906-909
7. Warnock D.W. Azole drug resistance in Candida species. J. Med. Microbiol. 37 (1992) 225-226
8. Saballs P., Torres-Rodígues M., and Salvadó M. La candidemia en el síndrome de inmunodeficiencia adquirida. Estudio retrospectivo de nueve casos. Rev. Iberoam. Micol. 17 (2000) 2-5
9. Sheehan D.J., Hitchcock C.A., and Sibley C.M. Current and emerging azole antifungal agents. Clinl. Microbiol. Rev. 12 (1999) 40-79
10. Sheehan D.J., Espinel-Ingroff A., Moore L.S., and Webb C.D. Antifungal susceptibility testing of yeasts: a brief overview. Clin. Infect. Dis. 17 (1993) 494-500
11. Monteil R.A., Madinier I., and Le Fichoux Y. In vitro antifungal resistance of oral Candida albicans strains in non-AIDS patients. Oral Microbiol. Immunol. 12 (1997) 126-128
12. Colombo A.L., Barchiesi F., McGough D.A., and Rinaldi M. Comparison of Etest and National Commitee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing. J. Clin. Microbiol. 33 (1995) 535-540
13. National Committee for Clinical Laboratory Standards, 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard M27-A2. NCCLS, Villanova, PA, USA
14. Sutton D.A., Fothergill A.W., and Rinaldi M.G. Clinically Significant Fungi (1998), Williams and Wilkins, Baltimor
15. Powderly W.G., Kobayashi G.S., and Herzig G.P. Amphotericin B-resistant yeasts infection in severely immunocompromised patients. Am. J. Med. 84 (1988) 826-832
16. Macura A.B. Fungal resistance to antimycotic drug: a growing problem. Int. J. Dermatol. 30 (1991) 181-183
17. Costa C.R., de Lemos J.A., Passos X.S., de Araujo C.R., Cohen A.J., Souza L.K., and Silva Mdo R. Species distribution and antifungal susceptibility profile of oral candida isolates from HIV-infected patients in the antiretroviral therapy era. Mycopathologia 162 (2006) 45-50
18. Alves S.H., Lopes J.O., and Cury A.E. Teste de Susceptibilidade aos Antifúngicos: Por que, quando e como realizar. News Laboratory 6 (1997) 140-148
19. Resende J.C.P., and Resende M.A. In vitro antifungal susceptibility of clinical isolates of Candida spp. from hospitalized patients. Mycoses 42 (1999) 641-644
20. Kurnatowski M., Kurnatowska A., and Wasowska-Krolikowska K. Activity of the azole drugs in vitro against strains of Candida albicans with different codes isolated from the digestive tract in children. Wiad Parazytol. 50 (2004) 387-392
21. Arcaya N.M., Mesa L.M., Pineda M.R., Beltran-Luengo H., and Milagros Calvo B. Profile of antifungal susceptibility of species of Candida isolated from hemocultures in a university hospital, Maracaibo, Venezuela. Rev. Iberoam. Micol. 23 (2006) 97-100
22. Skrodeniene, E., Dambrauskiene, A., Vitkauskiene, A., 2006. Susceptibility of yeasts to antifungal agents in Kaunas University of Medicine Hospital Medicina (Kaunas), vol. 42(4), pp. 294-299.
23. Nakamura T., and Takahashi H. Epidemiological study of Candida infections in blood: susceptibilities of Candida spp. to antifungal agents, and clinical features associated with the candidemia. J. Infect. Chemother. 12 (2006) 132-1388
24. Viscoli C. Fluconazole versus amphotericina B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a progmatic, multicentre, prospective and randomized clinical trial. Eur. J. Cancer 3 (1996) 814-820
25. Alexander B.D., and Perfect J.R. Antifungal resistance trends towards the year 2000. Drugs 54 (1997) 657-678
26. Swoboda-Kopec E., Wroblewska M., Rokosz A., Krawezyk E., and Luczac M. Susceptibility of clinical isolates of Candida glabrata to new triazoles. Int. J. Antimicrob. Ag. 21 (2003) 360-361
27. Colombo A.L., Barchiesi F., McGough D.A., and Rinaldi M.G. Comparison of Etest and National Commitee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing. J. Clin. Microbiol. 33 (1995) 535-540